These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12485941)

  • 1. Donor lymphocyte infusions as primary therapy for neoplasms.
    Montefusco V
    Blood; 2003 Jan; 101(1):373; author reply 373-4. PubMed ID: 12485941
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor lymphocyte infusions after reduced intensity conditioning allogeneic transplantation: what we need to know.
    Marks DI; Parker A; Robinson SP
    Blood; 2004 Jul; 104(1):295-6. PubMed ID: 15208210
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
    Bishop MR; Steinberg SM; Gress RE; Hardy NM; Marchigiani D; Kasten-Sportes C; Dean R; Pavletic SZ; Gea-Banacloche J; Castro K; Hakim F; Krumlauf M; Read EJ; Carter C; Leitman SF; Fowler DH
    Br J Haematol; 2004 Sep; 126(6):837-43. PubMed ID: 15352988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation.
    Champlin R; Giralt S; Gajewski J
    Acta Haematol; 1996; 95(3-4):157-63. PubMed ID: 8677736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplant outcome with donor specific buffy-coat and lymphocyte-transfused patients.
    Okazaki H; Takahashi H; Jimbo M; Iguro T; Satoh T; Ishizak M
    Transplant Proc; 1989 Feb; 21(1 Pt 2):1832-3. PubMed ID: 2652595
    [No Abstract]   [Full Text] [Related]  

  • 7. Adoptive immunotherapy:insights from donor lymphocyte infusions.
    Alyea E
    Transfusion; 2000 Apr; 40(4):393-5. PubMed ID: 10773047
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions.
    Dazzi F; Szydlo RM; Apperley JF; Goldman JM
    Blood; 2002 Oct; 100(7):2673-4. PubMed ID: 12360979
    [No Abstract]   [Full Text] [Related]  

  • 9. Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant.
    Yan CH; Wang Y; Wang JZ; Chen YH; Chen Y; Wang FR; Sun YQ; Mo XD; Han W; Chen H; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2016 Sep; 9(1):87. PubMed ID: 27629395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions.
    Ruiz-Genao DP; F-Peñas P; Daudén E; García-F-Villalta MJ; Fraga J; García-Diez A
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):632-4. PubMed ID: 16684312
    [No Abstract]   [Full Text] [Related]  

  • 11. Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions.
    Ljungman P; Lawler M; Lönnqvist B; Ringdén O; Shanwell A
    Bone Marrow Transplant; 1996 Dec; 18(6):1179-81. PubMed ID: 8971392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
    Nikiforow S; Kim HT; Daley H; Reynolds C; Jones KT; Armand P; Ho VT; Alyea EP; Cutler CS; Ritz J; Antin JH; Soiffer RJ; Koreth J
    Haematologica; 2016 Oct; 101(10):1251-1259. PubMed ID: 27354021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splenectomy status of the patient may have impact on response to donor lymphocyte infusions.
    Uckan-Cetinkaya D; Unal S; Cetin M; Sarikabadayi U; Aktaş D; Koç Y
    Leukemia; 2007 Sep; 21(9):2049-50; author reply 2050-1. PubMed ID: 17554372
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
    Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
    Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
    Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reduced-intensity hematopoietic stem cell transplantation and donor lymphocyte infusions for chronic myeloid leukemia].
    Ichinohe T; Ishikawa T
    Nihon Rinsho; 2003 Sep; 61(9):1573-8. PubMed ID: 14515726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism.
    Colvin GA; Berz D; Ramanathan M; Winer ES; Fast L; Elfenbein GJ; Quesenberry PJ
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):421-31. PubMed ID: 19285629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Kwon BS; Panoskaltsis-Mortari A; Kwak KB; Peschon JJ; Taylor PA
    J Immunol; 2001 Mar; 166(5):3174-83. PubMed ID: 11207270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation.
    Dey BR; McAfee S; Colby C; Cieply K; Caron M; Saidman S; Preffer F; Shaffer J; Tarbell N; Sackstein R; Sachs D; Sykes M; Spitzer TR
    Br J Haematol; 2005 Feb; 128(3):351-9. PubMed ID: 15667537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.